Literature DB >> 3896044

Blood flow properties and walking performance in chronic arterial occlusive disease.

B Angelkort, P Spürk, A Habbaba, M Mähder.   

Abstract

Recent investigations suggest an interdependence between blood fluidity and walking performance in patients with peripheral arterial occlusive disease (PAOD). Therefore, various blood fluidity variables (erythrocyte aggregation, erythrocyte flexibility, plasma viscosity, plasma proteins) were studied in groups of healthy subjects and claudicants with severe PAOD (exhausted perfusion reserve) receiving intravenous treatment with Trental (600 mg Pentoxifylline b.i.d., 21 days). Erythrocyte flexibility (expressed by filterability through micropore filters), red cell aggregation and plasma viscosity deteriorate with progression of disease especially in Stage IIb and III Fontaine classification, with walking distance below 150 m. Trental treatment resulted in patients with advanced POAD stages in improvement of red cell filterability, red cell aggregation, decrease of plasma viscosity, increase in absolute walking distance and relief from rest pain, suggesting that such patients are accessible to conservative treatment with hemorheologically active agents.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3896044     DOI: 10.1177/000331978503600504

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  8 in total

Review 1.  Pharmacological treatment of patients with peripheral arterial disease.

Authors:  Chin K Kim; Carsten M Schmalfuss; Richard S Schofield; David S Sheps
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Pentoxifylline in arterial disease of the legs.

Authors:  R Verhaeghe; M Verstraete
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study.

Authors:  G Ciuffetti; M Mercuri; C Ott; R Lombardini; R Paltriccia; G Lupattelli; L Santambrogio; E Mannarino
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Endothelial shear stress and blood viscosity in peripheral arterial disease.

Authors:  Young I Cho; Daniel J Cho; Robert S Rosenson
Journal:  Curr Atheroscler Rep       Date:  2014-04       Impact factor: 5.113

5.  24-h blood glucose pattern in type I and type II diabetics after oral treatment with pentoxifylline as assessed by artificial endocrine pancreas.

Authors:  S Raptis; A Mitrakou; D Hadjidakis; E Diamantopoulos; C Anastasiou; A Fountas; R Müller
Journal:  Acta Diabetol Lat       Date:  1987 Jul-Sep

Review 6.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.

Authors:  A Ward; S P Clissold
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

7.  The effect of denbufylline on the viscosity of rat whole blood and on the deformability (filterability) of rat blood cell suspensions.

Authors:  J J Jukna; C D Nicholson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

8.  Supervised Cycling Training Improves Erythrocyte Rheology in Individuals With Peripheral Arterial Disease.

Authors:  Chih-Chin Hsu; Yu-Ting Lin; Tieh-Cheng Fu; Shu-Chun Huang; Cheng-Hsien Lin; Jong-Shyan Wang
Journal:  Front Physiol       Date:  2022-01-05       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.